Indonesia to Produce COVID Vaccine for Its Own Exclusive Use

Yolanda Curtis
July 4, 2020

Bharat Biotech "is working expeditiously to meet the target, however, the final outcome will depend on the cooperation of all the clinical trial sites involved in the project", the ICMR letter said.

Zydus Cadila has been granted permission to conduct Phase I and Phase II clinical trials after successful animal trials, the official added.

Dr Ella, Chairman and Managing Director of the company has said, "When the company makes vaccines affordable to the common man we often get accused of creating something of low quality but we make vaccines believe that technology should reach the common man and no citizen should be deprived of healthcare solutions". India's Bharat Biotech and Zydus Cadila have received approval from the authorities to conduct human clinical trials of the vaccine against the disease.

India has taken a giant step towards discovering the cure of COVID-19.

"We are using our theory and we are optimistic that in the year 2021 and early 2021, this will be finished in the laboratory", the COVID-19 research team head said.


The vaccine is derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of virology.

According to Moderna, volunteers who have undergone the phase II trial in May have shown positive early results, developing antibodies against the virus.

Separately on Friday, Indian drugmaker Zydus Cadila said it had secured regulatory approval to start human trials on its own COVID-19 vaccine contender.

The 12 clinical trial sites include some of India's premier public institutions such as All India Institute of Medical Sciences (AIIMS-New Delhi), AIIMS-Patna, Nizam Institute of Medical Sciences (NIMS) - Hyderabad, Post Graduate Institute of Medical Sciences (PGIMS) - Rohtak, King George Hospital (KGH) - Visakhapatnam, among others.

'The furthest along in USA testing is an experimental vaccine from NIH's vaccine research center in partnership with Moderna, ' NIH Director Francis Collins said at Senate Appropriations hearing earlier on Thursday.


Other global vaccine candidates, who started human trials in April 2020 have just reached Phase 3 trials.

Apart from doing the sequencing, Indonesia is also collaborating with several countries, including South Korea, to develop a vaccine.

She says the pharmaceuticals planning advanced tests in humans shared their protocols for proposed trials with the agency; all were randomized experiments.

'Non-compliance will be viewed very seriously. "Therefore, you are advised to treat this project on highest priority and meet the given timelines without any lapse", the letter stated. Given the population, there is no single vaccine manufacturer that has all the capacity.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER